Berenberg starts ALK-Abello at buy on 'transformative' allergy push
BUZZ-Berenberg starts ALK-Abello at buy on 'transformative' allergy push ** Berenberg starts Danish allergy solutions maker ALK-Abello ALKb.CO with a "buy" rating, citing its "transformative" entry into food allergy treatments
** The broker expects ALK to advance its peanut allergy tablet into phase 3 trials in 2026, which could spark significant growth and profitability
** Berenberg forecasts a 14% three-year organic sales growth driven by paediatric tablet expansions and the launch of anaphylaxis adrenaline treatment neffy in new markets
** Rising allergy rates, driven by climate change and modern infant diets position ALK to capitalise on its 50% global share in allergy immunotherapy, the broker says
** It also notes that the peanut tablet showed superior desensitization compared to rivals in phase 2 trials, offering "best-in-class convenience" and better payer costs
** A strong net cash position of DKK 1.14 billion ($176.8 million) gives the firm significant firepower for M&A or new licensing deals without breaching debt targets
** Five out of six analysts rate it "strong buy"/"buy", one is on "hold" - LSEG
($1 = 6.4180 Danish crowns)
(Reporting by Vera Dvorakova)